Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02717611 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT02717611 · ClinicalTrials.gov record · last posted 2026-03-25

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Name: A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy — clinical trial record (NCT02717611)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 2

SponsorAcerta Pharma BV

Started2016-03-08

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

A Phase 2 Study to evaluate the Efficacy and Safety of ACP-196 (acalabrutinib) in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Amendment record 28 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 28 times since 2016-03-18; most recent amendment 2026-03-23. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2017-08-10

Status change Recruiting→Active, Not Recruitingv5

Trial Details

NCT Number	NCT02717611
Lead Sponsor	Acerta Pharma BV
Conditions	Chronic Lymphocytic Leukemia
Enrollment	60 participants
Start Date	2016-03-08
Primary Completion	2020-10-16 (estimated)
Study Completion	2026-06-06 (estimated)
Updated on ClinicalTrials.gov	2026-03-25